In the Field
CWMP is what keeps a wounded operator in the fight. The combination is designed to manage moderate pain without compromising airway, mentation, or hemostasis. Meloxicam is COX-2 selective, which means the platelet effects are minimal compared with aspirin or ibuprofen. Suzetrigine is the new addition in 2026 doctrine, addressing the moderate-pain space that previously required opioid escalation. Acetaminophen provides the antipyretic and additive analgesic effect. The whole pack is sized to ride in a pocket and be self-administered, which matters because the casualty is often their own first medic.
Common Mistake
Adding an opioid on top of a full CWMP for an operator who is still combat effective. The TCCC analgesia ladder is two-tracked: mission-capable casualties get CWMP only; non-mission-capable casualties get ketamine or esketamine and are removed from the fight. Stacking opioids on a still-functional operator is what the CWMP exists to avoid.
Technical Detail
TCCC 2026 CWMP composition: acetaminophen 1000 to 1300 mg PO every 8 hours (typically two 650 mg extended-release caplets); meloxicam 15 mg PO once daily (COX-2 selective NSAID with minimal antiplatelet effect, dosing interval supports operational pill burden); suzetrigine 100 mg PO once (two 50 mg tablets), then 50 mg PO every 12 hours. The suzetrigine addition in 2026 reflects accumulating data on the Nav1.8 sodium channel inhibitor as a non-opioid moderate-pain agent. CWMP is administered to any TCCC casualty who can still take PO meds and is functioning, regardless of subsequent escalation to ketamine if status changes.
